Bladder Cancer Coverage from Every Angle

Sumanta K. Pal, MD: Interpreting the Latest Results From the COSMIC-021 Study on Cabozantinib Plus Atezolizumab in Urothelial Carcinoma

Posted: Monday, June 13, 2022

Sumanta K. Pal, MD, of City of Hope National Medical Center, puts into perspective the findings on cabozantinib plus atezolizumab, and the encouraging clinical activity demonstrated in patients with inoperable locally advanced or metastatic urothelial carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.